Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

Tumor necrosis factor (TNF) inhibitors are widely used biologics for the treatment of several chronic inflammatory diseases. The launch of anti-TNF biosimilars has introduced the possibility of non-medical switching between originator biologics and their biosimilars. However, the potential clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Numan, Syed, Faccin, Freddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133136/
https://www.ncbi.nlm.nih.gov/pubmed/30084060
http://dx.doi.org/10.1007/s12325-018-0742-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133136/
https://www.ncbi.nlm.nih.gov/pubmed/30084060
http://dx.doi.org/10.1007/s12325-018-0742-9

Ejemplares similares